Todd Alonzo, PhD
Professor of Research Population and Public Health Sciences; Group Statistician for Children's Oncology Group
Todd Alonzo is a Professor of Research in the Department of Preventive Medicine, University of Southern California. He received his undergraduate degree at the California State Polytechnic University, San Luis Obispo, California in Statistics in 1994 and received both his MS and his PhD in Biostatistics in 1997 and 2000 from the University of Washington, Seattle. Dr. Alonzo's main areas of research interest are the statistical methods for analysis of biomarkers and medical diagnostic and screening tests, clinical trials, and the design and analysis of pediatric acute myelogenous leukemia studies. He has published over 245 peer-reviewed articles.
Dr. Alonzo has been member of the Editorial Board for Biometrics, Pediatric Blood Cancer, and Biometrical Journal and has acted as a reviewer for 30 scientific journals. He is a member of several Data Safety and Monitoring Boards. Dr. Alonzo was the President of the International Biometric Society Western Northern America Region (WNAR) in 2009. He is a Fellow of the American Statistical Association.
- Statistical Methods
- Research Design and Methods
Inefficiency of two-stage designs in phase II oncology clinical trials with high proportion of inevaluable patients.
Contemp Clin Trials. 2022 Jul 19;120:106849. doi: 10.1016/j.cct.2022.106849. Epub 2022 Jul 19. PubMed PMID: 35868503;
IL-10 and TNFα are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a children's oncology group report.
Pediatr Hematol Oncol. 2022 Jul 15;:1-12. doi: 10.1080/08880018.2022.2089790. Epub 2022 Jul 15. PubMed PMID: 35838057;
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
Leukemia. 2022 Jun 10;. doi: 10.1038/s41375-022-01622-0. Epub 2022 Jun 10. PubMed PMID: 35688939;
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
J Clin Oncol. 2022 Jul 10;40(20):2235-2245. doi: 10.1200/JCO.21.02840. Epub 2022 Apr 1. PubMed PMID: 35363510; PubMed Central PMCID: PMC9273373.
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
J Clin Oncol. 2022 Jul 10;40(20):2224-2234. doi: 10.1200/JCO.21.02838. Epub 2022 Mar 30. PubMed PMID: 35353553; PubMed Central PMCID: PMC9273376.
- Design of Clinical Studies